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Contribution 
 What are the novel findings of this work? 
The risk of fetal loss after amniocentesis or CVS in twin pregnancies is lower than 
previously reported, and there is no significant difference when comparing fetal loss before 
24 weeks of gestation or within 4 weeks from the procedure in twin pregnancies 
undergoing with those not undergoing invasive prenatal testing. 
 
 What are the clinical implications of this work? 
These data are intuitively helpful when counselling parents about the safety of the 
procedure, as a woman can be reassured that the overall risk of fetal loss is low, although 
clinicians should still highlight the higher rate of fetal loss in twins compared to singletons.
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ABSTRACT  
Objectives: To assess the rate of fetal loss following amniocentesis and chorionic villous 
sampling (CVS) in twin pregnancies. 
Methods:  Medline, Embase and Cochrane databases were searched for studies reporting 
procedure-related complications following amniocentesis or chorionic villous sampling in 
twin pregnancies. The primary outcome was the rate of procedure-related fetal loss. The 
secondary outcomes were fetal loss occurring before the 24th week of gestation and fetal 
loss occurring within 4 weeks after the procedure. Head-to-head meta-analyses were used 
to directly compare, for each outcome: (a) women undergoing amniocentesis versus 
women not undergoing amniocentesis, and (b) women undergoing CVS versus women not 
undergoing CVS, and to compute pooled risk differences between women exposed and 
not exposed to each invasive procedure. Additionally, meta-analyses of proportions were 
used to estimate the pooled rates of each of the three outcomes among women 
undergoing amniocentesis or CVS, and among controls, and head-to-head meta-analyses 
to directly compare, for each outcome: women undergoing amniocentesis versus women 
not undergoing amniocentesis; women undergoing CVS versus women not undergoing 
CVS.  
Results: Sixteen studies (3419 twin pregnancies undergoing and 2517 twin pregnancies 
not invasive procedures) were included. In twin pregnancies undergoing amniocentesis, 
head-to-head meta-analyses directly comparing women undergoing amniocentesis versus 
women not undergoing amniocentesis found a higher risk for overall fetal loss (OR 1.46, 
p=0.04; RD 0.013, p=0.04), while there was no difference when focusing on either fetal 
loss before 24 weeks of gestation (OR 1.59, p=0.06; RD 0.010, p=0.11) or fetal loss within 
4 weeks from the procedure (OR 1.38, p=0.3; RD 0.003, p=0.8). 
In twin pregnancies undergoing CVS, head-to-head meta-analyses directly comparing 
women undergoing CVS versus women not undergoing CVS found no significant 
difference either when investigating overall fetal loss (OR 1.61, p=0.5; RD 0.003, p=0.8) or 
fetal loss before 24 weeks of gestation (OR 1.61, p=0.5; RD 0.003, p=0.8). 
Conclusion:  The risk of fetal loss following amniocentesis and CVS in twins is lower than 
the one previously reported, and the rate of fetal loss before 24 weeks of gestation or 
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within 4 weeks from the procedure did not differ from the background risk of a twin 
pregnancy not undergoing invasive prenatal testing. These data can guide prenatal 
counselling for twin pregnancies undergoing invasive procedures.  
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INTRODUCTION  
Prenatal diagnostic invasive procedures, such as amniocentesis or chorionic villous 
sampling (CVS), are usually performed to rule out fetal chromosomal or biochemical 
anomalies, maternal transmittable infectious disease, and sometimes also performed for 
maternal request, when parental anxiety might significantly affect the pregnancy.1 
 The main concern for prenatal invasive testing is the risk of procedure-related fetal loss.1 
In singleton pregnancies, the risk of miscarriage after amniocentesis or CVS is low, 
ranging from 0.2% to 0.3%.2 
Twin pregnancies are at increased risk of perinatal mortality and morbidity compared to 
singletons,3-7 but the exact rate of procedure-related complications after invasive testing is 
still uncertain, with an estimated risk of fetal loss ranging from 2-4% in case of both 
amniocentesis and CVS, according to the International Society of Ultrasound in Obstetrics 
and Gynecology (ISUOG).1 
The most recent systematic review on this topic reported that the risk of pregnancy loss is 
likely to be increased by approximately 1% above the background risk in twin pregnancies 
following either amniocentesis or CVS, but this analysis dates back to almost ten years.8 In 
the meantime, other studies were published, also evaluating the association between the 
risk of fetal loss and chorionicity9 or entry technique10 (whether to perform amniocentesis 
through a single uterine entry, passing through the inter-twin membrane or through two 
different entries into the two amniotic sacs) and the risk appears to be lower than 
previously reported. 
The aim of this systematic review was to ascertain the actual rate of fetal loss following 
amniocentesis and CVS in twin pregnancies. 
 




Protocol, information sources and literature search  
This review was performed according to an a-priori designed protocol recommended for 
systematic reviews and meta-analysis.11-13 Medline, Embase and Cochrane databases 
were searched electronically on February 12, 2020 utilizing combinations of the relevant 
medical subject heading (MeSH) terms, key words, and word variants for “amniocentesis”, 
“chorionic villous sampling”, “miscarriage”, “fetal loss” and “twins”. The search and 
selection criteria were restricted to English language. Reference lists of relevant articles 
and reviews were hand searched for additional reports. Prisma guidelines were 
followed.14-16 The study was registered with the PROSPERO database (registration 
number CRD42020159940). 
  
Outcomes measures, study selection and data collection  
The primary outcome was the rate of overall fetal loss following amniocentesis or CVS in 
twin pregnancies, as defined by each author. Secondary outcomes were fetal loss 
occurring before the 24th week of gestation and fetal loss occurring within 4 weeks after 
the procedure. 
We also planned to perform sub-group analyses according to chorionicity (dichorionic vs 
monochorionic) and entry technique (single versus double).  
 
Only prospective and retrospective studies reporting data on amniocentesis or CVS in twin 
pregnancies were considered suitable for the inclusion. Studies reporting the outcome of 
invasive procedures in high order multiple gestations and those reporting the outcome of 
invasive procedures performed for fetal reduction were excluded. Pregnancies affected by 
chromosomal anomalies were also excluded from the analysis. Only full text articles were 
considered eligible for the inclusion. Case reports, conference abstracts and case series 
with fewer than five cases were excluded to avoid publication bias. Furthermore, studies 
published before 2000 were not included as advances in the field of invasive procedures 
and in the management of twin pregnancies make them less relevant.  
This article is protected by copyright. All rights reserved.
 
 
Two authors (DDM, FDA) reviewed all abstracts independently. Agreement regarding 
potential relevance was reached by consensus. Full text copies of those papers were 
obtained, and the same two reviewers independently extracted relevant data regarding 
study characteristics and pregnancy outcome. Inconsistencies were discussed by the 
reviewers and consensus reached or by discussion with a third author. If more than one 
study was published for the same cohort with identical endpoints, the report containing the 
most comprehensive information on the population was included to avoid overlapping 
populations.  
 
Quality assessment, risk of bias and statistical analysis 
Quality assessment of the included studies was performed using the Newcastle-Ottawa 
Scale (NOS) for cohort studies. According to NOS, each study is judged on three broad 
perspectives: the selection of the study groups; the comparability of the groups; and the 
ascertainment of the outcome of interest.17 Assessment of the selection of a study 
includes the evaluation of the representativeness of the exposed cohort, selection of the 
non-exposed cohort, ascertainment of exposure and the demonstration that the outcome 
of interest was not present at beginning of study. Assessment of the comparability of the 
study includes the evaluation of the comparability of cohorts on the basis of the design or 
analysis. Finally, the ascertainment of the outcome of interest includes the evaluation of 
the type of the assessment of the outcome of interest, length and adequacy of follow-up. 
According to NOS a study can be awarded a maximum of one star for each numbered 
item within the Selection and Outcome categories. A maximum of two stars can be given 
for Comparability.17   
 
In a sample of women with twin pregnancies, we evaluated the risk of fetal loss among 
women who underwent amniocentesis (vs no amniocentesis) or CVS (vs no CVS). Fetal 
loss was evaluated using three different approaches: (1) considering all cases of fetal loss 
(overall fetal loss); (2) considering only fetal losses occurring before the 24th week of 
gestation; (3) including only the cases occurring within 4 weeks after the procedure. 
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First, we set six head-to-head meta-analyses to directly compare, for each outcome: (1) 
women undergoing amniocentesis versus women not undergoing amniocentesis; (2) 
women undergoing CVS versus women not undergoing CVS. For this purpose, we 
included only studies having both arms of women undergoing versus not undergoing 
prenatal invasive testing, and we excluded those having only single-arm (i.e. only prenatal 
invasive testing). Furthermore, in these meta-analyses we included some cohort studies in 
which exposed and unexposed group sizes were severely unbalanced, and some studies 
that reported zero events in one or both of the compared groups. When the events are 
rare, many of the most commonly used meta-analytical methods may produce biased 
estimates.18-19 When the studies are also substantially imbalanced, the best performing 
methods are the Mantel-Haenszel odds ratio without zero-cell continuity corrections, 
logistic regression and an exact method.20-21 Mantel-Haenszel odds ratios cannot be 
computed in studies reporting zero events in both groups, the exclusion of which may 
however cause a relevant loss of information and the potential inflation of the magnitude of 
the pooled exposure effect.18 Therefore, to keep all studies into the analyses, the six head-
to-head meta-analyses were carried out using individual data random-effect logistic 
regression, with single study as the cluster unit, and the pooled datasets with individual 
data were reconstructed using published 2X2 tables. 
Second, we used the Mantel-Haenszel type method of Greenland and Robins22 to 
estimate, for each outcome, the pooled risk difference (and 95% confidence interval - CI) 
between the women undergoing and those not undergoing each invasive procedure. 
Providing pooled rates of fetal loss may be useful as introductory information to women 
contemplating having an invasive test. Therefore, as additional analyses, we performed 
meta-analyses of proportions to estimate the pooled rates of each of the three outcomes 
among women undergoing amniocentesis or CVS, and among controls. Proportion meta-
analyses were not used when only one study could be included (raw proportions and 95% 
confidence interval - CI - were reported in such cases), and a random-effect model was 
adopted to account for the inter-study heterogeneity. Additionally, all proportion meta-
analyses were first carried out including all pregnancies, then stratified according to 
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chorionicity - separately analyzing monochorionic (MC) and dichorionic twins (DC) - and 
number of needle insertions during the procedure (single- or double-needle). 
For each outcome, the total number of publications included in the meta-analyses was 
<10. We were thus unable to assess publication bias, either graphically, through funnel 
plots, or formally, through Egger's regression asymmetry test (in such cases, the power is 
too low to distinguish chance from real asymmetry).21 All analyses were carried out using 
Stata, version 13.1 (Stata Corp., College Station, TX, 2013), and StatsDirect Ltd. 
(StatsDirect statistical software. England: StatsDirect Ltd. 2013). 
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RESULTS   
 
Study selection and characteristics  
319 articles were identified, 27 were assessed with respect to their eligibility for inclusion 
and 16 studies9,10,23-36 were included in the systematic review (Table 1, Figure 1, 
Supplementary Table 1). 
Table 2 shows the definition of overall fetal loss provided by each author, the indication for 
invasive prenatal diagnosis and the exclusion criteria of each of the included studies. 
These sixteen studies9,10,23-36 included 3419 twin pregnancies undergoing invasive 
procedures and 2517 twin pregnancies not undergoing invasive prenatal diagnosis.  
Twin pregnancies included both DC and MC pregnancies, while we could not find any 
study reporting the occurrence of fetal loss exclusively in monoamniotic gestations.  
The results of the quality assessment of the included studies using the NOS scale are 
presented in Table 3. Most of the included studies showed an overall good score 
regarding the selection and comparability of study groups, and for ascertainment of the 
outcome of interest. The main weaknesses of these studies were their retrospective 
design, small sample size and heterogeneity of the outcomes observed. 
 
Synthesis of the results 
 
Amniocentesis 
Thirteen studies9,10,23,25-33,36 (5012 pregnancies) reported the occurrence of fetal loss in 
twin pregnancies undergoing amniocentesis. 
Head-to-head meta-analyses directly comparing women undergoing amniocentesis versus 
women not undergoing amniocentesis found a higher risk of overall fetal loss (6 studies9,25-
26,32-33,36: 60/1538 vs 71/2299; OR 1.46, p=0.04; RD 0.013, p=0.04), while there was no 
difference when focusing on either fetal loss before 24 weeks of gestation (5 studies25-26,32-
33,36: 36/1264 vs 31/1712; OR 1.59, p=0.06; RD 0.010, p=0.11) and fetal loss within 4 
weeks from the procedure (3 studies25-26,36: 25/977 vs 22/1172; OR 1.38, p=0.3; RD 0.003, 
p=0.8) (Table 4). 
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Overall, the rate of fetal loss was 2.4% (95% CI 1.4-3.6; 83/2713) compared with 2.4% 
(95% CI 0.9-4.6; 71/2299) for twin pregnancies not undergoing amniocentesis (Table 5; 
Figure 2). Eight9,23,25-27,31,32,36 (2383 pregnancies) and five9,25,26,32,33 (475 pregnancies) 
studies reported the occurrence of fetal loss in DC and MC twin pregnancies after 
amniocentesis, respectively. In DC pregnancies, the occurrence of fetal loss was 2.3% 
(95% CI 0.9-4.1, 38/1431); in MC gestations, fetal loss occurred in 2.3% (95% CI 0.1-6.4, 
12/278). When considering the number of needle insertions during the procedure, the rate 
of overall fetal loss in double needle insertion was 2.0% (95% CI 0.8-3.7, 59/2439), while 
the small number of studies reporting data on single needle insertion made it impossible to 
draw any convincing evidence for this subgroup analysis.  
The rate of fetal loss before 24 weeks of gestation was 2.1% (95% CI 1.4-2.9, 59/2439) in 
pregnancies undergoing amniocentesis compared with 1.7% (95% CI 0.8-2.9, 31/1712) in 
twin pregnancies not undergoing amniocentesis (Figure 3). When stratifying according to 
chorionicity, the rate of fetal loss before 24 weeks of gestation was 1.7% (95% CI 0.8-2.8, 
26/1237) in DC and 1.2% (95% CI 0.0-4.9, 7/155) in MC pregnancies. 
The rate of fetal loss occurring within 4 weeks from the procedure was 2.1% (95% CI 1.5-
2.9, 45/1932) in twin pregnancies undergoing amniocentesis compared with 1.8% (95% CI 
0.5-3.8, 22/1172) in twin pregnancies not undergoing amniocentesis (Figure S1). 
 
CVS 
Four studies24,28,34,35 (567 pregnancies) reported the overall risk of fetal loss in twin 
pregnancies undergoing CVS. 
Head-to-head meta-analyses directly comparing women undergoing CVS versus women 
not undergoing CVS found no significant difference either when focusing on overall fetal 
loss (2 studies24,35: 3/201 vs 5/218; OR 1.61, p=0.5; RD 0.003, p=0.8) and fetal loss before 
24 weeks of gestation (2 studies24,35: 3/201 vs 5/218; OR 1.61, p=0.5; RD 0.003, p=0.8) 
(Table 4). 
 Overall, the rate of fetal loss was 2.0% (95% CI 0.0-6.5; 8/349) compared with 1.8% (95% 
CI 0.3-4.2; 5/218) for twin pregnancies not undergoing CVS (Table 6; Figure 4). Two24,35 
(419 pregnancies) studies reported the occurrence of fetal loss in DC twin pregnancies, 
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while no study was found for MC pregnancies after CVS. In DC pregnancies, the 
occurrence of fetal loss was 0.5% (95% CI 0.0-2.2, 3/201). CVS in DC pregnancies was 
always performed with double needle insertion technique – thus leading to the same 
results (0.5%) - while no study reported data on single needle insertion.  
The rate of fetal loss before 24 weeks of gestation was 2.0% (95% CI 10.0-6.5; 8/349) 
compared with 1.8% (95% CI 0.3-4.2; 5/218) in twin pregnancies not undergoing CVS 
(Figure 5). When stratifying according to chorionicity, the rate of fetal loss before 24 weeks 
of gestation was 0.5% (95% CI 0.0-2.2, 3/201) in DC twin pregnancies. 
The rate of fetal loss occurring within 4 weeks from the procedure was 2.2% (95% CI 0.4-
11.8, 1/44), although this evidence comes from a single study (Figure S2).34 
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DISCUSSION  
Main findings  
Our findings show that the risk of fetal loss following amniocentesis and CVS in twin 
pregnancies is lower than previously reported in observational studies and guidelines.1,8 In 
particular, head-to-head meta-analyses showed that there is no significant difference in 
terms of fetal loss before 24 weeks of gestation or within 4 weeks from the procedure 
when directly comparing twin pregnancies which had invasive procedures (either 
amniocentesis or CVS) versus those which did not.  
 
Strengths and limitations  
The small number of cases in some of the included studies, their retrospective non-
randomized design, lack of standardized criteria for the surveillance after the procedure, 
the heterogeneity in the definition of fetal loss and the different indications for invasive 
prenatal testing represent the major limitations of this systematic review. Furthermore, 
some of the included studies also reported data of twin pregnancies complicated by 
structural anomalies, thus potentially increasing the rate of fetal loss, although lethal 
abnormalities were usually excluded. Moreover, the stratification according to chorionicity 
(dichorionic vs monochorionic twin pregnancies) included a lower number of cases, 
compared with the analysis including all twin pregnancies. Finally, some of the studies 
include also old data, and it is likely that some of the selection criteria for invasive testing 
are not comparable to our clinical setting. For this reason, we planned to perform a 
subgroup analysis on the last ten years, but the robustness of the results was significantly 
limited by the small number of studies and cases included. Despite these limitations, the 
present study represents the most up-to-date and comprehensive published review 
investigating the rate of fetal loss following amniocentesis and CVS in twin pregnancies. 
 
Comparison with other published evidence  
In 2012, a large systematic review by Argawal and Alfirevic reported higher rates of fetal 
loss after both amniocentesis and CVS which were estimated at 3.07% and 3.84%, 
respectively.8 In contrast to our findings, the authors also found a significantly higher risk 
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of pregnancy loss before 24 weeks when evaluating twin pregnancies undergoing or not 
amniocentesis, with an added risk of around 1% above the background risk.8 These data 
were also reported by the 2016 ISUOG guidelines on invasive procedures for prenatal 
diagnosis that describe a risk of fetal loss between 2.5% and 3.2% after amniocentesis 
and higher than 3% after CVS.1 
Similarly, another systematic review of 17 observational studies found that the pooled 
procedure-related loss rate before 24 weeks was 3.5% after amniocentesis, and the risk 
was 1.8 times higher, compared with women not undergoing amniocentesis.37 
The findings from this study show that the rate of fetal loss following amniocentesis and 
CVS is lower than currently stated and are quite consistent with the American College of 
Obstetricians and Gynecologists Practice Bulletin on prenatal diagnostic testing for genetic 
disorders where the attributable pregnancy loss rate of amniocentesis in twins is reported 
to be approximately 2%.38 
 
Clinical and research implications  
In the last decade, the spread of cell-free DNA (cfDNA) of maternal blood has significantly 
reduced the number of invasive procedures for prenatal genetic testing.1 cfDNA is the most 
sensitive screening method for common chromosomal anomalies (trisomy 21, 18, 13), with 
a detection rate of 99.7% for trisomy 21 and 97.9% for trisomy 18 in singleton 
pregnancies.39 Despite its excellent performance, cfDNA is still considered as a screening 
tool and a confirmatory invasive testing is needed in case of abnormal findings.40 
Furthermore, when focusing on twin pregnancies, the evidence on the accuracy on cfDNA 
is still an object of debate. A recent meta-analysis found that the detection rate for trisomy 
21 in twin pregnancies was 98.2%, and it was similar to what previously reported for 
singletons;41 conversely, the detection rate for trisomy 18 was 88.9% and it was lower 
compared with singleton pregnancies.41 However, the number of studies assessing the 
accuracy of cfDNA in twin pregnancies was limited and therefore the number of affected 
cases included in the analysis was significantly lower. For these reasons, international 
societies do not currently recommend cfDNA as a non-invasive prenatal testing in twin 
pregnancies.40,42 
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In this scenario, both amniocentesis and CVS play a fundamental role in prenatal genetic 
diagnosis in twin pregnancies, regardless of chorionicity. 
It is well known that in twin pregnancies, fetal morbidity and mortality are significantly 
higher than those of singletons3-7,43-47 – mostly depending on chorionicity and amnionicity 
– and a recent study showed that in gestations with two live fetuses at the end of the first 
trimester, the risk of pregnancy loss before 24 weeks was 2.2% in DC and 7.7% in MC 
diamniotic pregnancies,48 while the rate of intrauterine death of one fetus after week 22 
was 1.7%  in MC diamniotic and 0.6% in DC twins.49 
Of note, in our meta-analysis the rate of fetal loss before 24 weeks of gestation or within 4 
weeks from the procedure did not differ from the background risk of a twin pregnancy not 
undergoing invasive prenatal testing. 
These data are intuitively helpful when counselling parents about the safety of the 
procedure, as a woman can be reassured that the overall risk of fetal loss is low, although 
clinicians should still highlight the higher rate of fetal loss in twins compared to singletons. 
 
Conclusion 
The risk of fetal loss after amniocentesis or CVS in twin pregnancies is lower than 
previously reported, and there is no significant difference when comparing fetal loss before 
24 weeks of gestation or within 4 weeks from the procedure in twin pregnancies 
undergoing with those not undergoing invasive prenatal testing. Future large prospective 
studies sharing objective protocols might be useful to elucidate better the actual rates of 
miscarriage, short and long term procedure-related complications stratified according to 
chorionicity, single and double entry, number of attempts and indication for invasive 
testing. 
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Figure 1. Systematic review flowchart 
Figure 2. Pooled rates of fetal loss (overall) in women with twin pregnancies undergoing 
amniocentesis 
Figure 3. Pooled rates of fetal loss occurring before 24 weeks in women with twin 
pregnancies undergoing amniocentesis 
Figure 4. Pooled rates of fetal loss (overall) in women with twin pregnancies undergoing 
chorionic villus sampling  
Figure 5. Pooled rates of fetal loss occurring before 24 weeks in women with twin 
pregnancies undergoing chorionic villus sampling 
 
Supplementary Figure S1. Pooled rates of fetal loss occurring within 4 weeks from the 
procedure in women with twin pregnancies undergoing amniocentesis. 
 
Supplementary Figure S2. Pooled rates of fetal loss occurring within 4 weeks from the 
procedure in women with twin pregnancies undergoing chorionic villous sampling. 
 
Supplementary Table S1. Excluded studies and reason for the exclusion
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Table 1. General characteristics of the included studies 
 
 


































170 170 0 0 170 Yes No No Yes 




54 54 155 54 0 Yes No No Yes 




212 212 0 0 212 Yes No Yes No 




861 274 587 0 274 Yes Yes No Yes 
Lenis-Cordoba 2013 Spain 1990-
2010 
Prospective 661 396 265 0 396 Yes Yes No NR 
Kan 2012 China 1997-
2006 
Prospective 535 105 430 0 105 Yes Yes Yes Yes 




120 120 0 0 120 Yes No No NR 




204 204 0 104 100 NR No Yes Yes 
Daskalakis 2009 Greece 1993-
2006 
Prospective 442 442 0 0 442 Yes No No Yes 









Prospective 66 66 0 0 66 NR Yes No No 




380 132 248 0 132 NR Yes No Yes 




447 155 292 0 155 NR No No Yes 




379 379 0 44 335 Yes No No No 
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210 147 63 147 0 NR No No No 




953 476 477 0 476 NR No No Yes 
 
CVS: chorionic villous sampling; NR: not reported. 
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Table 2. Definition of fetal loss, indication for invasive prenatal diagnosis and exclusion criteria of each study 
 
Author Year Definition of 
fetal loss 
Indication for invasive procedure Exclusion criteria 
Kim 2019 Loss of one or 
two fetuses 
within 4 weeks 
Maternal age ≥ 35 years; abnormal maternal serum 
screening test results; increased NT; abnormal 
sonographic findings; chromosomal malformations in 
parents or previous pregnancies;  psychological 
indications; ICSI pregnancies. 
Known chromosome anomaly or lethal 
anatomical defects; demise of one twin at the 
time of the procedure; monochorionic or 
monoamniotic twin; repeated invasive 
procedure; pregnancies in which selective 
feticide was carried out  
Kim 2019 Miscarriage < 24 
weeks 
Maternal age ≥ 35 years; abnormal maternal serum 
screening test results; increased NT; abnormal 
sonographic findings; chromosomal malformations in 
parents or previous pregnancies;  psychological 
indications; ICSI pregnancies. 
Known chromosome anomaly or lethal 
anatomical defects; demise of one twin at the 
time of the procedure; monochorionic or 
monoamniotic twin; repeated invasive 
procedure; pregnancies in which SF was carried 
out; after abnormal karyotyping results of CVS 
Krispin 2019 Fetal loss within 
4 weeks 
Maternal age > 35 years; suspected anatomical 
anomalies; Cytomegalovirus seroconversion  
diagnosed during pregnancy 
Method of amniocentesis not clear or puncture 
made only in a single sac; termination of 
pregnancy; feticide of a single embryo; fetal 
chromosomal anomalies; monochorionic 
monoamniotic twins; missing data  
Sperling 2019 Fetal loss at any 
gestational age 
Pregnancies positive at the California Prenatal 
Screening Program; other unspecified indications 
Chromosomal/structural abnormalities; selective 
fetal reduction; terminations of pregnancy; 
neonatal deaths; ovum donation; incomplete 
data 
Lenis-Cordoba 2013 Fetal loss within 
4 weeks 
Maternal age; abnormal maternal serum test 
screening; abnormal NT  
Elective termination of pregnancy; previous 
CVS, AC performed earlier in gestation; 
selective reduction of triple gestation, 
monoamniotic twin pregnancies 
Kan 2012 Fetal loss within 
4 weeks 
maternal age over 35 years; history of abnormal 
babies; chromosomal anomalies; risk of hereditary 
disease in the fetuses 
Abnormal karyotype; structural anomalies; 
TTTS; missing data 
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Kalogiannidis 2011 Miscarriage < 24 
weeks 
Advanced maternal age; abnormal serum markers; 
ultrasound findings; family or previous history; 
infection; maternal anxiety; NTDs; carriers of 
thalassemia; others 
Monoamniotic twin pregnancy; previous CVS; 
embryo reduction in multiple gestations 
Simonazzi 2010 Loss of one or 
two fetuses < 24 
weeks 
Advanced maternal age; chromosomal anomalies in 
previous pregnancy; maternal request 
Triplet pregnancies; embryo reduction; selective 
termination 
Daskalakis 2009 Fetal loss within 
4 weeks 
Fetal karyotyping; DNA analysis for b thalassemia; 
congenital infection 
Chromosomal/structural abnormalities; selective 
fetal reduction; previous CVS; death of one 
fetus at the time of procedure; monochorionic 
pregnancy 
Supadilokluck 2009 Fetal loss within 
2 weeks 
Advanced maternal age; history of NTDs; history of 




2008 Fetal loss within 
2 weeks 
Advanced maternal age; previous abnormal child; 
abnormal US findings 
NR 
Millaire 2006 Loss of one or 
two fetuses < 24 
weeks 
NR Women who underwent amniocentesis before 
15 or after 17 weeks; previous CVS; higher 
order pregnancies; TTTS; early IUGR; lethal 
fetal anomalies; abnormal karyotype; 
monoamniotic twins 
Toth-Pal 2004 Miscarriage < 24 
weeks 
Advanced maternal age; US suspicious findings; ICSI 
pregnancy; parental concern; history of a child born 
with chromosomal anomalies; abnormal maternal 
serum testing results; history of Duchenne's muscular 
dystrophy; suspicion of Toxoplasma infection 
Structural or chromosomal anomalies; death of 
one fetus before amniocentesis 
Antsaklis 2002 Fetal loss within 
4 weeks 
advanced maternal age; history of chromosomal 
anomaly; abnormal serum biochemistry; abnormal US 
findings; congenital infections 
Chromosomal anomalies; monoamniotic 
pregnancy 
Brambati 2001 Fetal loss < 20 
weeks 
Fetal karyotyping NR 
Yukobowich 2001 Fetal loss within 
4 weeks 
Advanced maternal age; abnormal serum 
biochemistry; maternal request; US suspicious 
structural anomalies, death of one fetus before 
the procedure; selective feticide 
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findings 
NT, nuchal translucency; CVS, chorionic villous sampling;  NR, not reported; TTTS,  twin-twin transfusion  syndrome;  NTDs, neural 
tube defects;  IUGR, intrauterine growth restriction;  US, ultrasound
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Table 3. Quality assessment of the included studies according to Newcastle-Ottawa Scale (NOS) for cohort studies; a study can be 
awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can 
























Author Year Selection Comparability Outcome 
Kim 2019    
Kim 2019    
Krispin 2019    
Sperling 2019    
Lenis-Cordoba 2013    
Kan 2012    
Kalogiannidis 2011    
Simonazzi 2010    
Daskalakis 2009    
Supadilokluck 2009    
Hanprasertpon
g 
2008    
Millaire 2006    
Toth-Pal 2004    
Antsaklis 2002    
Brambati 2001    
Yukobowich 2001    











Table 4. Results of the meta-analyses evaluating the association between each invasive procedure (amniocentesis and chorionic 
villus sampling) and fetal loss in twin pregnancies. For each outcome, pooled risk differences between women undergoing and not 
undergoing invasive procedures were also computed 
 
 A. Amniocentesis  B. Chorionic villus sampling 









 N. of studies 
(total 
sample) 
Raw data* Pooled OR 
(95% CI) Pooled RD 
(95% CI) 
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3. 
Fetal loss within 4 
weeks 













 -- -- --  
 
OR = Odds ratio. CI = Confidence Interval. RD = Risk difference. 
* Number of events / Total n. of subjects in the exposed group (women undergoing A. amniocentesis or B. chorionic villus sampling) 
versus Number of events / Total n. of subjects in the unexposed group (women not undergoing invasive procedures).  
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Table 5. Pooled rates of each outcome in twin pregnancies which had amniocentesis versus those which did not. Data from single 
studies have been combined using proportion meta-analysis (random-effect model) 
 
 Amniocentesis  No amniocentesis 
Outcomes n / Na Pooled % 
(95% CI) 
 n / Na Pooled % 
(95% CI) 
      
1. Overall fetal loss      
      
- All twins 83 / 2713 2.4 (1.4-3.6)  71 / 2299 2.4 (0.9-4.6) 
      
- Dichorionic twins only 38 / 1431 2.3 (0.9-4.1)  19 / 952 1.9 (0.1-6.0) 
      
- Monochorionic twins only 12 / 278 2.3 (0.1-6.4)  16 / 197 7.9 (4.4-12.2) 
      
- Single needle insertion only 0 / 65 0.0 (0.0-0.4)*  -- -- 
      
- Double needle insertion only 16 / 591 2.0 (0.8-3.7)  7 / 265 2.6 (1.3-5.4)* 
      
      
2. Fetal loss <24th gestational week      
      
- All twins 59 / 2439 2.1 (1.4-2.9)  31 / 1712 1.7 (0.8-2.9) 
      
- Dichorionic twins only 26 / 1237 1.7 (0.8-2.8)  5 / 740 0.7 (0.2-1.4) 
      
- Monochorionic twins only 7 / 155 1.2 (0.0-4.9)  5 / 97 5.2 (2.2-11.5)* 
      
      
3. Fetal loss occurring within 4 weeks from the 45 / 1932 2.1 (1.5-2.9)  22 / 1172 1.8 (0.5-3.8) 
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procedure 
      
 
CI = Confidence Interval.   a Number of women with the outcome / Total number of women.   * Only one study available. 
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Table 6. Pooled rates of each outcome in twin pregnancies which had chorionic villus sampling versus those which did not. Data from 
single studies have been combined using proportion meta-analysis (random-effect model)  
 
 Chorionic villus 
sampling 
 No chorionic villus 
sampling 
Outcomes n / Na Pooled % 
(95% CI) 
 n / Na Pooled % 
(95% CI) 
      
1. Overall fetal loss      
      
- All twins 8 / 349 2.0 (0.0-6.5)  5 / 218 1.8 (0.3-4.2) 
      
- Dichorionic twins only 3 / 201 0.5 (0.0-2.2)  5 / 218 1.8 (0.3-4.2) 
      
- Monochorionic twins only -- --  -- -- 
      
- Single needle insertion only -- --  -- -- 
      
- Double needle insertion only 3 / 201 0.5 (0.0-2.2)  5 / 218 1.8 (0.3-4.2)  
      
      
2. Fetal loss <24th gestational week      
      
- All twins 8 / 349 2.0 (0.0-6.5)  5 / 218 1.8 (0.3-4.2) 
      
- Dichorionic twins only 3 / 201 0.5 (0.0-2.2)  5 / 218 1.8 (0.3-4.2) 
      
- Monochorionic twins only -- --  -- -- 
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3. Fetal loss occurring within 4 weeks from the 
procedure 
1 / 44 2.2 (0.4-11.8)*  0 / 0 -- 
      
 
CI = Confidence Interval. aNumber of women with the outcome / Total number of women. * Only one study 
available  
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